1) Gnant M, Thomssen C and Harbeck N. St. Gallen/Vienna 2015: a brief summary of the
consensus discussion. Breast Care 2015;10:124–130.
2) Tseng OL, Spinelli JJ, Gotay CC, Ho WY, McBride ML, Dawes MG. Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis 2018;10(4):71-90.
3) Monnier A. Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol 2007;18(8):36-44.
4)Tarafdar S, Lim LT, Collins CE, Ramaesh K. Tamoxifen keratopathy as seen with in-vivo
confocal microscopy. Seminars in ophthalmology 2012;27: 27-8.
5) Paganini-Hill. A, Clark. LJ. Eye problems in breast cancer patients treated with tamoxifen.
Breast cancer research and treatment 2000;60:5.
6) Gianni L, Panzini I, Li S, et al. Ocular toxicity during adjuvant chemoendocrine therapy for
early breast cancer: results from International Breast Cancer Study Group trials. Cancer 2006;106:505-13.
7) Srikantia N, Mukesh S, Krishnaswamy M. Crystalline maculopathy: a rare complication of
tamoxifen therapy. Journal of cancer research and therapeutics 2010;6:313-5.
8) Chung SE, Kim SW, Chung HW, Kang SW. Estrogen antagonist and development of
macular hole. Korean journal of ophthalmology 2010;24:306-9.
9) Doshi RR, Fortun JA, Kim BT, Dubovy SR, Rosenfeld PJ. Pseudocystic foveal cavitation
in tamoxifen retinopathy. American journal of ophthalmology 2014;157:1291-8.
10) Ersoz MG, Arf S, Karacorlu M, Hocaoglu M, Muslubas IS. Pachychoroid Pigment Epitheliopathy Associated with Tamoxifen. Ophthalmic Surg Lasers Imaging Retina 2017;48:838-842.
11) Onder HI, Kilic AC, Kose SA, et al. Branch retinal vein occlusion associated with
tamoxifen use. Seminars in ophthalmology 2013;28:88-90.
12) Bolukbasi S, Erden B, Cakir A. Pachychoroid Pigment Epitheliopathy and Choroidal Thickness Changes in Coeliac Disease. J Ophthalmol 2019; doi: 10.1155/2019/6924191.
13) A. Alwitry, I Gardner. Tamoxifen maculopathy. Arch Ophthalmol. 2002;120(10):1402.
14) S.G. Nayfield, M.B. Gorin, Tamoxifen-associated eye disease. A review. J Clin Oncol 1996;14(3):1018-26.
15) Rishi R. Doshi, Jorge A. Fortun, Brian T. Kim, Sander R. Dubovy, Philip J. Rosenfeld. Pseudocysytic foveal cavitation in tamoxifen retinopathy. Am J Ophthalmol 2014;157(6):1291-1298.
16) Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 2016;36:499-516.
17) Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: A review of epidemiology and pathophysiology. Clin Exp Ophthalmol 2013;41(2):201-214.
18) Nudleman E, Witmer MT, Kiss S, Williams GA, Wolfe JD. Central serous chorioretinopathy in patients receiving exogenous testosterone therapy. Retina
2014;34(10):2128-2132.
19) Witmer MT, Klufas MA, Kiss S. Polycystic ovary syndrome and central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina 2015;46(6):684-686.
20) Maruko I, Iida T, Sugano Y et al. Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease. Retina 2011;31:510-7.
21) Gundogan FC, Akay F, Uzun S et al. Choroidal Thickness Changes in the Acute Attack Period in Patients with Familial Mediterranean Fever Ophthalmologica 2016;235:72-77.
22) Kobayashi K, Kobayashi H, Ueda M. Honda Y. Estrogen receptor expression in bovine
and rat retinas. Invest Ophthalmol Vis Sci 1998;39:2105-10.
23) Ogueta SB, Schwartz SD, Yamashita CK, Farber DB. Estrogen receptor in the human eye: influence of gender and age on gene expression. Invest Ophthalmol Vis Sci 1999;40:1906-11.
24) Koulisis N, Moysidis SN, Olmos de Koo LC, Russell CA, Kashani AH. The tipping point: Tamoxifen toxicity, central serous chorioretinopathy, and the role of estrogen and its receptors. Am J Ophthalmol Case Rep 2016 May 18;3:8-13.
25) Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res 2015;48:82-118.
26) Baumgart J, Nilsson K, Stavreus Evers A, et al. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients. Climacteric 2014;17(1):48-54.
27) Yildiz O, Seyrek M. Vasodilating mechanisms of testosterone. Exp Clin Endocrinol Diabetes 2007;115(1):1-6.
28) Cho KS, Yoon YH, Choi JA, Lee SJ, Koh JY. Induction of autophagy cell death by tamoxifen in cultured retina pigment epithelial and photoreceptor cells. Invest Ophthalmol Vis Sci. 2012;53(9):5344-53.
29) Huang-Link Y-M, Al-Hawasi A, Lindehammar H. Acute optic neuritis: retinal ganglion cell loss precedes retinal nerve fiber thinning. Neurol Sci 2015; 36: 617–620.
30) Vieira LM, Silva NF, Dias dos Santos AM, dos Anjos RS, Pinto LA, Vicente AR, Borges BI, Ferreira JP, Amado DM, da Cunha JP. Retinal ganglion cell analysis by optical coherence tomography in toxic and nutritional optic neuropathy. J Neuroophthalmol 2015;35(3):242-5.
31) Demirok G, Kocamaz F, Topalak Y, Altay Y, Sengun A. Macular ganglion cell complex thickness in acute and chronic central serous chorioretinopathy. Int Ophthalmol
2017;37(2):409-416.
32) Rochon-Duvigneaud A (1907) Recherches sur la fovea de la rétine humaine et particulièrement sur le bouquet des cônes centraux. Archives d’Anatomie Microscopique 9:315–342.
33) A. Shiono, J. Kogo, G. Klose et al. Photoreceptor outer segment length: a prognostic factor for idiopathic epiretinal membrane surgery,” Ophthalmology 2013;120(4):788-94.
34) Uslu H, Gurler B, Yildirim A, Tatar MG, Kantarcı FA, Goker H, Pehlevan HS, Colak HN. Effect of Hydroxychloroquine on the Retinal Layers: A Quantitative Evaluation with Spectral-Domain Optical Coherence Tomography. J Ophthalmol 2016; doi: 10.1155/2016/8643174.